ConductScience.org, home

Paper35455686

The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis.

Wolfe HR and 2 others. J Pers Med, 2022. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis. Papers, record 35455686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35455686

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis.
PubMed
Journal
J Pers Med
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Relative citation ratio, by iCite
0
iCite
Revised in PubMed
2022-07-16
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wolfe HRHeather Rhttps://orcid.org/0000-0003-2076-6487
2Horwitz MEMitchell E
3Rein LAMLindsay A M

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References57

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126970380Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.Biol Blood Marrow Transplant2016https://conductscience.org/library/papers/26970380PubMed
217151367The myeloproliferative disorders.N Engl J Med2006https://conductscience.org/library/papers/17151367PubMed
322375971A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.N Engl J Med2012https://conductscience.org/library/papers/22375971PubMed
412920019Allogeneic hematopoietic stem cell transplantation for myelofibrosis.Blood2003https://conductscience.org/library/papers/12920019PubMed
524986690Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.Blood2014https://conductscience.org/library/papers/24986690PubMed
610331505Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.Am J Hematol1999https://conductscience.org/library/papers/10331505PubMed
728561069A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.Leukemia2017https://conductscience.org/library/papers/28561069PubMed
824292520Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.Bone Marrow Transplant2014https://conductscience.org/library/papers/24292520PubMed
926916563Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.Leuk Lymphoma2016https://conductscience.org/library/papers/26916563PubMed
1024389309
Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Haematologica2014https://conductscience.org/library/papers/24389309PubMed
118426474Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction.Leukemia1993https://conductscience.org/library/papers/8426474PubMed
1226181658Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.JAMA Oncol2015https://conductscience.org/library/papers/26181658PubMed
1316834459MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.PLoS Med2006https://conductscience.org/library/papers/16834459PubMed
1430408564Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.Biol Blood Marrow Transplant2019https://conductscience.org/library/papers/30408564PubMed
1529791053Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis.Eur J Haematol2018https://conductscience.org/library/papers/29791053PubMed
1629800615Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation.Biol Blood Marrow Transplant2018https://conductscience.org/library/papers/29800615PubMed
1719879949Outcome of transplantation for myelofibrosis.Biol Blood Marrow Transplant2010https://conductscience.org/library/papers/19879949PubMed
1820425397Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.Curr Hematol Malig Rep2010https://conductscience.org/library/papers/20425397PubMed
1922212965One thousand patients with primary myelofibrosis: the mayo clinic experience.Mayo Clin Proc2012https://conductscience.org/library/papers/22212965PubMed
2020439618Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis.Blood2010https://conductscience.org/library/papers/20439618PubMed

See all 57 referencesDownload CSV of references

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35455686

GET https://conductscience.org/api/papers/v1/35455686/references?page=2